Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03228537 · OUTCOME

Overall Survival (OS)

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma · Source last updated 2026-08-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
3 years after the last accrual

What was measured

From date of initial registration to date of death due to any cause. Participants last known to be alive are censored at date of last contact.

Analysis population: Eligible and evaluable participants.

Groups in this outcome

Treatment (Chemotherapy, Surgery +/- RT, Maintenance)

NEOADJUVANT: Patients receive atezolizumab IV over 30-60 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Cycles repeats every 21 days for 4 cycles in the absence of disease progression or unexpected toxicity. SURGERY: Within 21-90 days after completion of neoadjuvant therapy, patients undergo extrapleural pneumonectomy (EPP) or pleurectomy/decortication (PD). Patients who undergo EPP will then undergo radiation therapy. MAINTENANCE: Within 90 days after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Chemotherapy, Surgery +/- RT, Maintenance)28

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Chemotherapy, Surgery +/- RT, Maintenance)31.5Not reported18.4NALess than half of the remaining participants died (more than half are still alive) after reaching the median survival.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Less than half of the remaining participants died (more than half are still alive) after reaching the median survival.
        group Id
        OG000
        lower Limit
        18.4
        upper Limit
        NA
        value
        31.5
denoms
  1. counts
    1. group Id
      OG000
      value
      28
    units
    Participants
description
From date of initial registration to date of death due to any cause. Participants last known to be alive are censored at date of last contact.
dispersion Type
95% Confidence Interval
groups
  1. description
    NEOADJUVANT: Patients receive atezolizumab IV over 30-60 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Cycles repeats every 21 days for 4 cycles in the absence of disease progression or unexpected toxicity. SURGERY: Within 21-90 days after completion of neoadjuvant therapy, patients undergo extrapleural pneumonectomy (EPP) or pleurectomy/decortication (PD). Patients who undergo EPP will then undergo radiation therapy. MAINTENANCE: Within 90 days after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity.
    id
    OG000
    title
    Treatment (Chemotherapy, Surgery +/- RT, Maintenance)
param Type
MEDIAN
population Description
Eligible and evaluable participants.
reporting Status
POSTED
time Frame
3 years after the last accrual
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice